Home > Boards > US Listed > Medical - Equipment > Guardion Health Sciences Inc. (GHSI)

NEWS...Guardion(R) Announces Statistically Significant Blood Assay Study Results

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
chubbs27 Member Profile
 
Followed By 37
Posts 1,997
Boards Moderated 0
Alias Born 09/06/13
160x600 placeholder
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 1/13/2020 4:50:34 PM
Guardion® Appoints Experienced Executive to Lead Development and Expansion of Recently-Acquired NutriGuard Business Line GlobeNewswire Inc. - 1/7/2020 11:02:10 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 12/30/2019 4:48:20 PM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 12/30/2019 4:47:16 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 12/30/2019 4:45:30 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 12/10/2019 4:24:02 PM
Guardion Health Sciences, Inc. Reports Results for the Three and Nine Months Ended September 30, 2019 GlobeNewswire Inc. - 11/14/2019 7:00:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 11/13/2019 5:27:30 PM
Guardion Health Sciences Closes $8.4 Million Underwritten Public Offering GlobeNewswire Inc. - 10/30/2019 12:33:22 PM
Guardion Health Sciences Announces Pricing of $8.4 Million Underwritten Public Offering GlobeNewswire Inc. - 10/28/2019 9:21:39 AM
Guardion® Receives approval from USPTO for expanded claims for its Proprietary Medical Device, the MAPCAT SF GlobeNewswire Inc. - 10/23/2019 7:00:05 AM
Guardion® Announces Statistically Significant Blood Assay Study Results GlobeNewswire Inc. - 10/10/2019 10:30:00 AM
Guardion Health Sciences Acquires the NutriGuard Brand of Products GlobeNewswire Inc. - 9/23/2019 10:30:00 AM
Guardion Launches VectorVision CSV-2000 Standardized Contrast Sensitivity Test GlobeNewswire Inc. - 9/3/2019 7:00:00 AM
Guardion Health Sciences Closes $5.8 Million Underwritten Public Offering GlobeNewswire Inc. - 8/15/2019 4:05:00 PM
Guardion Health Sciences Announces an Increase in the Pricing of its Previously Announced Underwritten Public Offering GlobeNewswire Inc. - 8/15/2019 8:35:14 AM
Guardion Health Sciences Announces Pricing of $5.2 Million Underwritten Public Offering GlobeNewswire Inc. - 8/13/2019 9:00:00 AM
Guardion Health Sciences Reports June 30, 2019 Interim Results of Operations GlobeNewswire Inc. - 8/12/2019 8:40:00 AM
Foundation Fighting Blindness selects Guardion’s VectorVision CSV-1000 Diagnostic Instrument for Use in Large-Scale Multi-C... GlobeNewswire Inc. - 8/6/2019 7:00:00 AM
Guardion’s Proprietary Medical Device, the MapcatSF®, Receives Patent from the Hong Kong Patents Registry GlobeNewswire Inc. - 7/17/2019 7:00:00 AM
Guardion’s Proprietary Medical Device, the MapcatSF®, Receives Patent from the European Union GlobeNewswire Inc. - 6/20/2019 7:00:00 AM
Guardion Launches Second Ocular Health Formula ‘GlaucoCetin’ GlobeNewswire Inc. - 6/4/2019 7:00:00 AM
Guardion’s Lumega-Z Formula Associated with Substantial Clinical Improvement in Patients Contrast Sensitivity Visual Functi... GlobeNewswire Inc. - 5/9/2019 10:14:43 AM
Guardion's Lumega-Z Formula Associated with Improved Vision in Patients with Severe Glaucoma GlobeNewswire Inc. - 5/7/2019 7:00:00 AM
Guardion Health Sciences, Inc. Receives Official Trademark Registrations in China GlobeNewswire Inc. - 5/1/2019 7:00:00 AM
chubbs27   Thursday, 10/10/19 10:47:18 AM
Re: None
Post # of 583 
NEWS...

Guardion(R) Announces Statistically Significant Blood Assay Study Results

Study Results Show 40 Times Higher Blood Concentration Levels of Mesozeaxanthin From Lumega-Z, Guardion's Flagship Medical Food, as compared to Standard AREDS2 Over-The-Counter Gel Caps

San Diego, California, Oct. 10, 2019 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. ("Guardion" or the "Company") (Nasdaq: GHSI) announced the formal results of a blood assay study that established that Lumega-Z, Guardion's proprietary medical food designed specifically to replenish and restore the eye's macular protective pigment, provided 40 times higher concentrations and bioavailability of mesozeaxanthin in the blood as compared to over-the-counter AREDS2 gel cap supplements.

The study was conducted by Professor Richard A. Bone, BSc, PhD, a member of the faculty of the Department of Physics at Florida International University in Miami, Florida. Dr. Bone is also a member of the Company's Scientific Advisory Board. Dr Bone was the first scientist to note the presence of mesozeaxanthin in the macular protective pigment and to suggest its importance in macular health. The study results are currently being prepared for publication in late 2019.

David Evans, PhD, Guardion's Chief Science Officer, commenting on this large disparity in the blood concentration levels resulting from the ingestion of Lumega-Z as compared to AREDS2 gel cap supplements, stated, "Considerable research demonstrates the importance of mesozeaxanthin for protecting the macular region of the retina and staving off vision loss due to macular degeneration. The results of this IRB-approved clinical study clearly show the potent nature of our proprietary formula and further explain the beneficial results observed and documented in patients with eye disease receiving Lumega-Z.

@Knowchit
Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist